1241897-98-2

Usage

Heterocyclic compound

A compound containing a pyrimidine ring This refers to the structure of the compound, which includes a ring of atoms with at least one heteroatom (an atom other than carbon or hydrogen, in this case, nitrogen).

Benzylamino group

An amino group attached to a benzyl group This is one of the functional groups present in the compound, which contributes to its potential biological activities and pharmaceutical applications.

Carbonitrile functional group

A cyano group (C≡N) attached to an sp-hybridized carbon atom This is another functional group present in the compound, which can participate in various chemical reactions and contribute to its versatility in organic synthesis.

Attached at the 2 and 5 positions

The benzylamino group is attached to the 2nd position and the carbonitrile group is attached to the 5th position of the pyrimidine ring This describes the specific locations of the functional groups on the pyrimidine ring, which can influence the compound's properties and reactivity.

Potential pharmaceutical applications

The compound may be used in the development of new drugs targeting various diseases This highlights the potential for the compound to be used in medicine due to its unique structure and properties.

Versatile compound

The compound has potential applications in various fields, including medicine and chemistry This emphasizes the wide range of possible uses for 2-(benzylamino)pyrimidine-5-carbonitrile, making it a valuable addition to the field of chemistry.

Upstream product

• 38373-55-6 benzyl-(5-bromo-pyrimidin-2-yl)-amine 
• 544-92-3 copper(I) cyanide 
• 100-46-9 benzylamine 

Downstream Products

• 1246749-79-0 N-benzyl-5-(2H-tetrazol-5-yl)pyrimidin-2-amine 
• 1241898-00-9 ethyl {5-[2-(benzylamino)pyrimidin-5-yl]-2H-tetrazol-2-yl}acetate 
• 1241896-60-5 [5-(2-{4-[2-(trifluoromethyl)benzoyl]piperidin-1-yl}pyrimidin-5-yl)-2H-tetrazol-2-yl]acetic acid 

Relevant academic research and scientific papers

NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Heteroaromatic compounds of structural formula I are selective inhibitors of stearoyl- coenzyme. A delta-9 desaturase (SCDl) relative to other known stearoyl-coenzyme. A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis. Formula (I).

HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Heterocyclic compounds of structural formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a R1— substituted heteroaryl, R1 is an heteroaryl ring substituted with an ester or carboxylic acid containing radical, X-T is N—CR5R6, C═CR5 or CR13—CR5R6, Y is a bond or —C(O)—, a and b represent an integer selected from 1 to 4, and Ar is an optionally substituted phenyl or naphtyl, are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD) The heterocyclic compounds are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis, obesity, diabetes, neurological disease, Metabolic Syndrome, insulin resistance, cancer, liver steatosis, and non-alcoholic steatohepatitis.

HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Heterocyclic compounds of structural formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a R1-substituted heteroaryl, R1 is an heteroaryl ring substituted with an ester or carboxylic acid containing radical, X-T is N-CR5R6, C=CR5 or CR13-CR5R6, Y is a bond or -C(O)-, a and b represent an integer selected from 1 to 4, and Ar is an optionally substituted phenyl or naphtyl, are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD) The heterocyclic compounds are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis, obesity, diabetes, neurological disease, Metabolic Syndrome, insulin resistance, cancer, liver steatosis, and non-alcoholic steatohepatitis.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Heterocyclic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; Metabolic Syndrome; insulin resistance; cancer, liver steatosis; and non-alcoholic steatohepatitis.